Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) Bundle
Founded in 1990, Jinghua Pharmaceutical Group Co., Ltd. has grown into a powerhouse with a registered capital of 860 million yuan, total assets of 8.479 billion yuan and a workforce of over 3,900 employees (including more than 230 doctors and masters), positioning the company to pursue its mission of "careful protection of health" through focused leadership in neuropsychiatry and cardiovascular fields, sustained R&D investment, and deep collaborations with institutions like the Shanghai Institute of Pharmaceutical Industry, Shanghai Institute of Organic Chemistry (CAS) and Zhejiang University-read on to explore how Jinghua's pragmatic, innovative, inclusive and win‑win values translate into strategic ambitions, multi-site manufacturing (Xinchang, Hangzhou, Shangyu, Shandong, Bayannaoer, Shenzhen, Shenyang) and a vision to lead China's mental and cardiovascular therapeutic sectors.
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) - Intro
Founded in 1990, Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) has evolved into a diversified pharmaceutical enterprise focused on R&D, production, and sales across prescription drugs, APIs, and healthcare formulations. The organization combines sizeable manufacturing capacity, academic partnerships, and a growing asset base to support innovation-driven development.
- Registered capital: 860 million RMB
- Total assets: 8.479 billion RMB
- Employees: >3,900 (including >230 with doctoral or master's degrees)
- Primary production and operation sites: Xinchang, Hangzhou, Shangyu, Shandong, Bayannaoer, Shenzhen, Shenyang
| Metric | Value |
|---|---|
| Year established | 1990 |
| Registered capital | 860,000,000 RMB |
| Total assets | 8,479,000,000 RMB |
| Employees | 3,900+ |
| Senior R&D talent | 230+ (doctorates & masters) |
| Listed ticker | 002349.SZ |
Mission
To research, produce, and deliver high-quality, accessible pharmaceutical products that improve patient outcomes and public health, while advancing pharmaceutical science through continuous innovation and collaboration.
- Commitment to quality: stringent GMP-compliant production across multiple sites
- Patient-centric focus: develop treatments addressing clinical needs and population health
- Accessible healthcare: scale production to improve drug availability in domestic and export markets
Vision
To become a leading, innovation-driven pharmaceutical group recognized for scientific excellence, diversified product portfolios, and sustainable growth that benefits patients, partners, employees, and shareholders.
- Innovation leadership: deepen R&D pipelines via internal teams and external partnerships
- Operational excellence: optimize asset utilization across 7+ production locations
- Global reach: expand market presence beyond China while maintaining regulatory compliance
Core Values
- Integrity - rigorous compliance, transparent governance, and responsible manufacturing
- Scientific rigor - evidence-based R&D and collaboration with top research institutes
- Quality first - consistent product safety and efficacy across all facilities
- People-centered - invest in talent (230+ advanced-degree researchers) and employee growth
- Sustainability - prudent financial stewardship (8.479 billion RMB assets) and long-term partnerships
Strategic enablers
- R&D collaborations: Shanghai Institute of Pharmaceutical Industry, Shanghai Institute of Organic Chemistry (CAS), Zhejiang University, and other academic partners
- Integrated manufacturing: multiple specialized sites enabling API, formulation, and sterile product capabilities
- Human capital: deep technical bench with >230 doctoral/master-level researchers supporting pipeline development
For a deeper look at the company's financials and investor-relevant metrics, see: Breaking Down Jinghua Pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) - Overview
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) centers its corporate purpose on the 'careful protection of health,' with strategic emphasis on neuropsychiatry and cardiovascular therapeutics. The company frames innovation as the indispensable route to long-term development and concentrates resources to translate scientific advances into clinically and commercially meaningful products.
- Mission emphasis: protection of public health through focused pharmaceutical solutions in psycho‑neural and cardiovascular domains.
- Strategic ambition: to take the lead in psycho‑neural and cardiovascular fields by building category leadership and differentiated therapies.
- Operational credo: "innovation as the only path" - sustained R&D investment, technology breakthroughs, and capability building to form durable core competitiveness.
Core corporate values are expressed succinctly as pragmatic, innovative, inclusive, and win‑win - guiding decision making from clinical development and manufacturing to partner relationships and market expansion.
- Pragmatic: evidence‑driven project selection and lifecycle management focused on patient outcomes and commercial viability.
- Innovative: prioritizing high‑value R&D to address unmet needs in neuropsychiatry and cardiovascular medicine.
- Inclusive: collaborative partnerships across hospitals, CROs, and academic institutions; internal culture nurturing talent.
- Win‑win: alignment with healthcare stakeholders to create shared value - patients, payers, providers, partners, and shareholders.
| Metric (Unit) | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (RMB millions) | 2,850 | 3,210 | 3,640 |
| Net profit (RMB millions) | 320 | 385 | 420 |
| R&D spend (RMB millions) | 160 | 230 | 310 |
| R&D as % of revenue | 5.6% | 7.2% | 8.5% |
| Employees (approx.) | 3,600 | 3,900 | 4,200 |
| Market segments (primary) | Neuropsychiatry, Cardiovascular, Central Nervous System therapeutics | ||
R&D and innovation lie at the heart of Jinghua's mission execution. To operationalize 'pursuing valuable innovation,' the company has focused investment and organizational systems on:
- Pipeline depth: progressing multiple clinical and preclinical programs in CNS and cardiovascular indications, with a mix of small molecules and formulation innovations.
- R&D capability: expanding in‑house medicinal chemistry, pharmacology, and clinical development teams while partnering with academia and contract research organizations.
- Technology breakthroughs: prioritizing key technology platforms (e.g., novel CNS delivery approaches, fixed‑dose cardiovascular combinations) to shorten time‑to‑market and enhance differentiation.
- Regulatory & quality systems: strengthening compliance and manufacturing scale to support domestic and incremental export growth.
Key performance indicators reinforcing the mission and vision:
- R&D intensity rising to ~8.5% of revenue in 2023 from ~5.6% in 2021, reflecting sustained prioritization of innovation.
- Top‑line CAGR (2021-2023) ~13% - revenue growth driven by expansions in core therapeutic categories and increased market penetration.
- Employee growth to ~4,200 in 2023 supports expanded clinical development, regulatory, and manufacturing activities.
Strategic initiatives aligned with the goal to lead psycho‑neural and cardiovascular fields include targeted M&A for pipeline acceleration, selective licensing partnerships to access complementary assets, and capacity investments to ensure supply stability for key products. Jinghua communicates its corporate story and strategic rationale in detail for stakeholders here: Jinghua Pharmaceutical Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) - Mission Statement
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) positions its mission around improving population health through innovation in mental health, cardiovascular disease (CVD) and related therapeutic areas. The mission translates into integrated R&D, manufacturing, regulatory strategy and commercialization efforts designed to raise standards of care in China and to expand selectively into international markets.- Deliver clinically effective, safe and affordable medicines focused on mental and cardiovascular health.
- Drive innovation via targeted R&D investments and partnerships to accelerate pipeline assets from discovery through commercialization.
- Ensure manufacturing quality and supply-chain resilience to meet growing domestic demand and export opportunities.
- Maintain compliance, ethical sales practices and patient-centric pharmacovigilance across all markets.
- R&D focus: prioritize CNS (antipsychotics/antidepressants), cardiovascular (antihypertensives, lipid-lowering agents), and cerebrovascular supportive therapies.
- Commercial focus: expand hospital and retail penetration for core products and grow specialty channel coverage in tertiary hospitals.
- Scale & quality: achieve GMP/ISO certifications across major plants and target continuous improvement in production yields and batch-release times.
| Metric | Target / Context |
|---|---|
| China mental health pharmaceuticals market (approx.) | RMB 100-150 billion (2023 est.), CAGR ~7% (2021-2026) |
| China cardiovascular drug market (approx.) | RMB 200-260 billion (2023 est.), CAGR ~5-8% |
| R&D investment intensity (company target) | Increase R&D spend to 8-12% of revenue within 3 years |
| Manufacturing capacity goal | Expand sterile/solid-dose capacity by 20-30% to support new launches (3-year plan) |
| Hospital coverage objective | Top-tier (tertiary) hospital listings for 3-5 core products in each therapeutic area within 2 years |
- Patient-first: prioritize patient safety, access and outcomes in product design and lifecycle management.
- Scientific rigor: ground decisions in clinical evidence, regulatory standards and real-world data.
- Integrity & compliance: uphold transparent governance, ethical commercial conduct and full regulatory compliance.
- Collaboration: build partnerships with academic institutions, biotech firms and clinical networks to accelerate innovation.
- Sustainability: pursue resource-efficient manufacturing and corporate social responsibility in community health initiatives.
- Pipeline prioritization: allocate funding to late-stage CNS and CVD candidates with high unmet need and clear regulatory pathways.
- Commercial execution: strengthen key account management in cardio/neurology departments and increase reimbursement-access initiatives.
- Quality & compliance investment: certify additional production lines to international GMP standards and expand pharmacovigilance capabilities.
- Data-driven development: integrate real-world evidence and registries to support label expansion and health-economics dossiers.
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) - Vision Statement
Jinghua Pharmaceutical Group Co., Ltd. anchors its corporate identity on a clear vision: to become a leading, research-driven integrated pharmaceutical group that continuously delivers high-quality therapeutics and healthcare solutions to improve patient outcomes domestically and internationally. This vision is operationalized through strategic R&D investment, production capacity expansion, and collaboration across industry and academia. Core values - pragmatic, innovative, inclusive, and win-win - are embedded across Jinghua's strategy and operations:- Pragmatic: focus on evidence-based decision-making, cost-efficient manufacturing, and measurable operational KPIs to ensure reliable supply chains and product quality.
- Innovative: continuous investment in drug discovery, formulation technology, and process optimization to accelerate pipeline progression and generics/innovative product competitiveness.
- Inclusive: fostering internal talent development, supplier partnerships, and open collaboration with research institutes and hospitals to broaden access and capability.
- Win-win: pursuing commercial models and partnerships that deliver shared value for patients, investors, partners, and employees.
| Indicator | Most recent annual/period figure | Notes |
|---|---|---|
| Revenue (FY) | RMB 3.6 billion | Reflects consolidated sales across prescription drugs, APIs, and OTC products |
| Net profit (FY) | RMB 420 million | Reported net income after taxes and minority interests |
| R&D expenditure | RMB 310 million (≈8.6% of revenue) | Investment in new molecules, formulation upgrades, and clinical trials |
| Gross margin | 38.5% | Supported by improved mix of higher-value products and cost controls |
| Employees | ~4,200 | R&D, manufacturing, sales, and administrative staff across domestic sites |
| Export / international sales share | ~18% | Established export channels for APIs and selected finished products |
| 5-year revenue CAGR | ~11.5% | Driven by product launches and market expansion |
| Year of establishment | 1997 | Over two decades of industry presence |
- Pragmatic execution: streamlining production lines to raise capacity utilization by targeted percentage points and shortening order-to-delivery lead times.
- Innovation pipeline: prioritizing therapeutic areas with high unmet need, sponsoring clinical trials, and progressing multiple candidates through IND/NDA milestones; R&D budget maintained at a high-single-digit share of revenue.
- Inclusive growth: talent programs, supplier development, and local community health projects to strengthen social license to operate.
- Win-win partnerships: licensing, co-development, and distribution agreements that align revenue sharing and risk allocation-expanding market reach while sharing R&D burden.
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.